Esperion Therapeutics ( (ESPR) ) has released its Q1 earnings. Here is a breakdown of the information Esperion Therapeutics presented to its investors.
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in developing and marketing non-statin, oral medications for cardiovascular disease, focusing on unmet patient needs in the healthcare sector.
In its first quarter of 2025, Esperion reported a total revenue of $65 million, marking a 53% year-over-year decrease primarily due to a one-time milestone received in 2024. However, when adjusted for this milestone, the revenue actually grew by 63%. The U.S. net product revenue saw a significant increase of 41% year-over-year, reaching $34.9 million.
Key highlights from the quarter include the expansion of Esperion’s development portfolio with a new program targeting Primary Sclerosing Cholangitis (PSC), a market with an estimated value exceeding $1 billion. The company also achieved a milestone of over one million prescriptions for its bempedoic acid products in the U.S. and strengthened its reimbursement support, which is expected to drive future growth. Additionally, Esperion’s global partnerships continue to yield positive results, with significant market penetration in Europe and anticipated approvals in Japan and Canada.
Despite the revenue growth, Esperion reported a net loss of $40.5 million for the quarter, compared to a net income of $61 million in the same period last year. The company ended the quarter with $114.6 million in cash and cash equivalents. Looking ahead, Esperion remains focused on its growth strategies, including advancing its pipeline and expanding its global footprint, as it anticipates further market approvals and increased product adoption.